Belyea to step down as Metabolic CEO

By Renate Krelle
Thursday, 13 January, 2005

Obesity drug-developer Metabolic (ASX:MBP) announced today that the company is searching for a new CEO and that when an appointment is made, founding CEO Chris Belyea will move into a "scientific and technical" role within the company.

The company said Belyea had expressed his desire to relinquish the CEO role in August 2004. Board chairman Arthur Emmett has since been undertaking the search for a new CEO.

Related News

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

AI won’t restart your plant: Why practical skills matter more than ever

POSCO Holdings steps up HILT CRC partnership

Melbourne company gets funding for new battery manufacturing model

Hazer and KBR complete commercial-scale hydrogen plant design

Calibration explained: principles, processes and modern reporting

  • All content Copyright © 2026 Westwick-Farrow Pty Ltd